Hospital
Sampson Regional Medical Center
Sampson Regional Medical Center was paid $9.00M by Medicaid between Jan 2018 and Dec 2024, across 107 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoSAMPSON REGIONAL MEDICAL CENTER
CLINTON, NC 28328
CLINTON, NC 28328
33aNPI1609857432assigned 11/09/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.00M
24GClaims314,582
24DCodes billed107
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#54 of 92
Median peer was paid$11.47M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,179 | $887K | |
| 2019 | 42,147 | $846K | |
| 2020 | 34,674 | $584K | |
| 2021 | 35,650 | $980K | |
| 2022 | 46,838 | $1.63M | |
| 2023 | 56,137 | $2.08M | |
| 2024incomplete | 55,957 | $1.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 36,628 | 34,048 | $2.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 11,852 | 11,000 | $1.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.2% | 8,117 | 7,621 | $738K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.1% | 16,469 | 15,419 | $731K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.0% | 12,727 | 11,792 | $448K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 1,540 | 1,424 | $331K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.9% | 19,913 | 9,495 | $258K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.7% | 4,830 | 4,329 | $244K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 285 | 256 | $211K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 6,704 | 6,225 | $204K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 28,582 | 25,811 | $198K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 10,809 | 9,498 | $173K |
95 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 3,409 | $157K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 271 | $156K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.7% | 5,796 | $156K |
| 80053 | Comprehensive metabolic panel | 1.6% | 20,364 | $147K |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 4,058 | $141K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 4,710 | $111K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,733 | $87K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,333 | $77K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 525 | $65K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,308 | $65K |
| 87430 | <1% | 3,678 | $60K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,846 | $58K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,750 | $54K |
| 87088 | <1% | 6,791 | $54K | |
| 81025 | <1% | 6,671 | $51K | |
| 83605 | <1% | 5,007 | $48K | |
| 84484 | <1% | 7,022 | $45K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,073 | $41K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,450 | $37K |
| 81001 | <1% | 11,657 | $34K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 886 | $29K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 497 | $28K |
| 83690 | <1% | 3,613 | $22K | |
| 87420 | <1% | 1,234 | $22K | |
| 82553 | <1% | 2,901 | $19K | |
| 81003 | <1% | 7,553 | $16K | |
| 82550 | <1% | 3,406 | $13K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,866 | $12K |
| 83880 | <1% | 525 | $10K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 285 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 135 | $8K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 142 | $7K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 93 | $7K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,039 | $7K |
| 86787 | <1% | 402 | $6K | |
| 86703 | <1% | 420 | $6K | |
| 83735 | <1% | 1,316 | $6K | |
| 87040 | <1% | 1,100 | $5K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 162 | $5K |
| 80055 | <1% | 171 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 359 | $5K |
| 87186 | <1% | 584 | $5K | |
| 87077 | <1% | 584 | $4K | |
| 87210 | <1% | 953 | $4K | |
| 86850 | <1% | 337 | $4K | |
| 86762 | <1% | 260 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 27 | $4K |
| 80061 | Lipid panel | <1% | 195 | $3K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 25 | $3K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 20 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 744 | $2K |
| 87340 | <1% | 230 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 18 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 971 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 367 | $2K |
| 82150 | <1% | 338 | $2K | |
| 85610 | <1% | 745 | $2K | |
| 74018 | <1% | 44 | $2K | |
| 87081 | <1% | 173 | $2K | |
| 88142 | <1% | 89 | $2K | |
| 86592 | <1% | 310 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 485 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 41 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 59 | $1K |
| J3490 | Unclassified drugs | <1% | 106 | $1K |
| 86901 | <1% | 313 | $1K | |
| 86900 | <1% | 313 | $1K | |
| 82950 | <1% | 150 | $959.09 | |
| 80299 | <1% | 62 | $954.12 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 73 | $796.62 |
| 86140 | <1% | 151 | $744.19 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 252 | $723.98 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 158 | $684.87 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,187 | $625.94 |
| 85660 | <1% | 82 | $545.26 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 13 | $502.20 |
| 72100 | <1% | 13 | $300.04 | |
| 85730 | <1% | 91 | $284.41 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 196 | $250.47 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 120 | $224.11 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $223.19 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 125 | $142.63 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 29 | $142.53 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 169 | $128.71 |
| 85379 | <1% | 12 | $126.12 | |
| A9270 | Non-covered item or service | <1% | 114 | $84.93 |
| 84100 | <1% | 15 | $68.95 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 12 | $55.72 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 31 | $51.20 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 34 | $38.94 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 48 | $22.65 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 52 | $14.87 |
| 80375 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHEINZMAN, GERALD (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Sampson Regional Emergency Professional Services, LLC | Clinton, NC | $4.02M |
| Sampson Regional Medical Center | Clinton, NC | $94K |
| Sampson Regional Medical Services LLC | Clinton, NC | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.